Growth Hormone for the Treatment of Gastroparesis

Recruiting now · Early Phase 1

Conditions studied: Gastroparesis

In brief

The purpose of this study is to determine whether treatment with Growth Hormone results in symptomatic improvement in patients with gastroparesis.

Key facts

Study ID

NCT06803589

Run by

Mayo Clinic

People needed

10

Starts

2024-10-22

Expected to finish

2027-12-01

Last updated by the study team

2026-04-16

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Symptoms > 6 months that have not responded satisfactorily to standard treatment.
• For gastroparesis: Gastroparesis Cardinal Symptom Index (GCSI) score of >21

You may not qualify if…

• Known history of GH deficiency, hypothalamic or pituitary disease
• Diabetes
• Prior use of GH therapy
• Age-adjusted low serum IGF1
• Women on oral estrogen therapy6
• Pregnancy or nursing
• History of malignant solid tumors
• Obesity (BMI > 30)History of coronary and thromboembolic diseases.
• History of sarcoidosis
• History of pituitary surgery
• History of thyroid nodules.
• Any other condition, which in the opinion of the investigator would impede compliance or hinder completion of the study.
• Failure to give informed consent.

Where it is running

• Mayo Clinic — Phoenix, Arizona, United States (enrolling)
• Mayo Clinic in Arizona — Scottsdale, Arizona, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.